These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18456237)

  • 1. Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo.
    Klebanoff MA; Meis PJ; Dombrowski MP; Zhao Y; Moawad AH; Northen A; Sibai BM; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Leveno KJ; Miodovnik M; Conway D; Wapner RJ; Carpenter M; Mercer BM; Ramin SM; Thorp JM; Peaceman AM;
    Am J Obstet Gynecol; 2008 Nov; 199(5):506.e1-7. PubMed ID: 18456237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
    Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
    Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
    Della Torre M; Enakpene C; Ravangard S; DiGiovanni L; Deyo K; Whelan A; Sutherland M; Fischer J
    Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
    Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
    Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
    Awwad J; Usta IM; Ghazeeri G; Yacoub N; Succar J; Hayek S; Saasouh W; Nassar AH
    BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
    Bustos ML; Caritis SN; Jablonski KA; Reddy UM; Sorokin Y; Manuck T; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Peaceman AM; Mercer BM; Sciscione A; Rouse DJ; Ramin SM;
    Am J Obstet Gynecol; 2017 Sep; 217(3):369.e1-369.e9. PubMed ID: 28522317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate in a Statewide Population-Based Cohort of Medicaid Enrollees.
    Wang X; Garcia SM; Kellom KS; Boelig RC; Matone M
    Am J Perinatol; 2023 Dec; 40(16):1770-1780. PubMed ID: 34784617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
    Stetson B; Hibbard JU; Wilkins I; Leftwich H
    Obstet Gynecol; 2016 Nov; 128(5):983-988. PubMed ID: 27741201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The use of progestatives for the prevention of spontaneous preterm birth].
    Azria E
    J Gynecol Obstet Biol Reprod (Paris); 2016 Dec; 45(10):1280-1298. PubMed ID: 27776845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial.
    Lim AC; Bloemenkamp KW; Boer K; Duvekot JJ; Erwich JJ; Hasaart TH; Hummel P; Mol BW; Offermans JP; van Oirschot CM; Santema JG; Scheepers HC; Schöls WA; Vandenbussche FP; Wouters MG; Bruinse HW;
    BMC Pregnancy Childbirth; 2007 Jun; 7():7. PubMed ID: 17578562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does progesterone treatment influence risk factors for recurrent preterm delivery?
    Meis PJ; Klebanoff M; Dombrowski MP; Sibai BM; Leindecker S; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S
    Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
    Saghafi N; Khadem N; Mohajeri T; Shakeri MT
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
    Meis PJ; Klebanoff M; Thom E; Dombrowski MP; Sibai B; Moawad AH; Spong CY; Hauth JC; Miodovnik M; Varner MW; Leveno KJ; Caritis SN; Iams JD; Wapner RJ; Conway D; O'Sullivan MJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
    N Engl J Med; 2003 Jun; 348(24):2379-85. PubMed ID: 12802023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.